In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis - Wikidata - awgldk - TriplyDB

In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis

In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis

http://www.wikidata.org/entity/Q36553502

about

Cirrhosis: new research provides a basis for rational and targeted treatments Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets Lack of the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) attenuates liver fibrogenesis in mice Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization Effects of c-myb antisense RNA on TGF-beta1 and beta1-I collagen expression in cultured hepatic stellate cells Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver Current status of novel antifibrotic therapies in patients with chronic liver disease Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver Differential expression of hepatic fibrosis mediators in sick and spontaneously recovered mice with experimental biliary atresia An herbal formula, CGX, exerts hepatotherapeutic effects on dimethylnitrosamine-induced chronic liver injury model in rats.Alternative splicing of endothelial fibronectin is induced by disturbed hemodynamics and protects against hemorrhage of the vessel wall Role of alphavbeta6 integrin in acute biliary fibrosis Regulation of cholangiocyte proliferation.TGFbeta1 in liver fibrosis: time to change paradigms?Suppression of CB1 cannabinoid receptor by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats.Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats Preliminary experimental study of urethral reconstruction with tissue engineering and RNA interference techniques.Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection.Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1 Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation Hepatitis C and liver fibrosis.Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury.Pathogenesis and management of alcoholic hepatitis.Research progress of vasculopathy in portal hypertension.Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ.Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform.Targeted treatments for cirrhosis.Enhanced effect of soluble transforming growth factor-beta receptor II and IFN-gamma fusion protein in reversing hepatic fibrosis.Anti-TGF-beta strategies for the treatment of chronic liver disease.Antifibrotic agents for liver disease.Oral administration of recombinant adeno-associated virus-mediated bone morphogenetic protein-7 suppresses CCl(4)-induced hepatic fibrosis in mice.Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection Emerging therapies for liver fibrosis.

P2860

Q24527263-433B50F4-79BF-4AE9-A4E0-3C58BEEE0062 Q24792944-9DA8CB28-AE21-4627-B0F5-DEF7A74E644F Q24793319-9D3B1DA7-9946-4983-AB96-FDDE52B7D18C Q24809810-BA8D6F91-CCB7-49F6-8041-54A38EA78701 Q27316480-49C22036-E5F3-4E74-961A-13BD9723A277 Q28077583-781CF954-5FE4-44EE-A601-E83F515622F8 Q28303698-969AA506-B597-4500-B961-E7F552CEC913 Q28486111-FB2168AA-CDB7-473D-BA65-A4483EECDF42 Q28567374-C1131945-64FE-44E4-A243-F9DAF5037DE6 Q28576895-7AF5CAA3-7934-4ED0-8F7D-F5EEA8992462 Q29616840-7F21A5EB-B0AD-478F-B052-3B8F24C735DC Q30473375-82BF116A-4809-4914-B1CE-8BFFD55B413E Q33583361-B48A8D60-A551-49EF-B2BF-31BCAE35099D Q33749232-A4E4B9D7-386F-47AE-8F15-07E9E9967719 Q33868992-6EE2D4C3-34CD-45AA-9172-B07BB644CA95 Q34076187-A5A22D0F-4D86-4DC0-B17C-2AB78D1E7A27 Q34088326-7007A093-BFA7-4361-B74D-4290AA39B565 Q34229378-DA57DEE8-EE70-4EA2-AE75-B50EF84657A9 Q34322705-DAAB9119-53D3-4B26-9C1F-0F9E7CB07780 Q34515920-AF9F3F47-44ED-4675-8B15-0B8CDC517E4C Q34563199-E7511414-BF27-4ACA-BE48-30691FED8F1C Q34642580-AC0AA79A-D48D-4AB9-9B72-4EE179E770D6 Q34792468-500BB366-DDBF-4BB8-8788-7BA1FA43AA76 Q34832951-5235A94A-E9FE-4D0A-8C3A-8F6A3077F9E5 Q35010511-327E75F1-C387-47CF-AF17-CC9AD9F1E48A Q35070050-0BEB277A-FE8F-4828-AB49-F8C514AEC62F Q35088302-73000EA7-9060-4D08-AEC1-D398BCFEF80D Q35091476-802EB55F-DF13-4BFE-981F-F53F01056FB7 Q35597135-E6CE5443-6A89-45C0-B122-71CAF535AC2E Q35607638-21EA5F6C-95DB-467B-AE12-90570E8128CD Q35621292-3436A571-D758-481F-A37B-A3086DAE769A Q35649446-CC4D4FCE-1B3E-48E6-817A-56843112A854 Q35793352-F33716D8-38DB-4161-AE42-C6C3ACFAA447 Q35911123-D466E583-7284-402D-A16C-AF4362B7A265 Q36326462-4F18C505-4899-4B62-9BF7-75894816296F Q36339566-EA44AC4D-F018-4864-93A0-F546C06F3EB0 Q36376477-E4FD1F1A-733A-4949-8741-B51F19099A92 Q36401061-17EEF721-43A7-489C-A7B6-338325DCBC9D Q36410515-BB0FBBC6-2BF1-475A-B454-2857C7AF8BA5 Q36478124-83FDE31E-53F9-4366-8CB9-C8A61FE31533

P2860

In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis

http://www.wikidata.org/entity/Q36553502

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@ast

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@en

type

label

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@ast

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@en

prefLabel

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@ast

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@en

P1433

Q36553502-F9AAC0A5-D08F-4C3F-AB3E-7AA0614CBDE4

P1476

Q36553502-1E94EA53-2BE5-4DB6-BA72-B0432D794252

P2093

Q36553502-103249AC-BAD2-466C-B896-51937BA3F8CF

Q36553502-618F1DB1-3587-4B37-8BEC-E8FAA97DB11E

Q36553502-E577740C-BB7A-4DB4-8747-133B595BF8DD

Q36553502-FDE5CF55-E4E3-4F9D-8049-6ADDD49E50D7

P2860

Q36553502-0263CD9E-C785-4BDB-9FC7-ED436CBBF406

Q36553502-03348048-0482-44CC-BF3D-F38FDBC53191

Q36553502-0D047BA4-210C-46DD-887D-637163B2251D

Q36553502-11B3B055-A534-45CA-B806-0A22F7279CD7

Q36553502-11DD1FAE-CAF6-4790-BF9B-CD0326D1A30B

Q36553502-15D0A05B-DCCE-4E2D-822E-1AC7F8A96F96

Q36553502-1684B7A4-7396-4C8F-BA3D-84C0E7E2A4F3

Q36553502-227B3C16-01D7-4583-81A5-3AA35E4F2343

Q36553502-2387C7C0-D2B5-4781-A310-E04A2DCD23C9

Q36553502-25C30F8D-57B6-4952-AA05-7C404C1F9A10

P304

Q36553502-DD456A7E-61D0-49F1-A1B0-4E2FA42B1292

P31

Q36553502-13137D3A-FCEB-4A55-B5BC-BBF98CBC50E6

P356

Q36553502-FB2E9E73-50B2-4E31-91E1-0623FFC01F1C

P407

Q36553502-9501BEA3-DDC6-41B5-9383-97E56F9C4B3C

P433

Q36553502-00BADAEC-C17D-447F-B62B-93BEB1615AFE

P478

Q36553502-414F96CC-FE76-4257-843D-F8628A1BA9DB

P577

Q36553502-C28E289E-7513-4A3D-83D4-A4F8B8DFB962

P5875

Q36553502-48E85AD9-F64D-4E2A-A7A6-33841C32F8AC

P698

Q36553502-4DB92094-8212-4393-9441-FA0A73E28D71

P932

Q36553502-B00D60B6-CB58-4C3D-8FB2-0F8304BB9403

P356

PNAS.96.22.12719

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

In vivo inhibition of rat stel ...... w therapy for hepatic fibrosis

@en

P2093

D M Bissell

http://www.w3.org/2001/XMLSchema#string

D Roulot

http://www.w3.org/2001/XMLSchema#string

J George

http://www.w3.org/2001/XMLSchema#string

V E Koteliansky

http://www.w3.org/2001/XMLSchema#string

P2860

Primary structure of human ribosomal protein S14 and the gene that encodes it

The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands

Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors

TGF beta signals through a heteromeric protein kinase receptor complex

Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin

Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium

Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

Epidemiology of hepatitis C

P304

12719-12724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.22.12719

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12764642

http://www.w3.org/2001/XMLSchema#string

P698

10535989

http://www.w3.org/2001/XMLSchema#string

P932

23066

http://www.w3.org/2001/XMLSchema#string